SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02202200

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib

An open label multicentre, phase I-II study with tumour molecular pharmacodynamics (MPD) evaluation and pharmacokinetics of PD-0332991 added to vemurafenib in patients suffering metastatic melanoma with BR. The main objective is to establish the Maximum Tolerated Dose (MTD) of PD-0332991 when added to standard vemurafenib therapy (960 mg BID). The estimated MTD is defined as the dose of PD-0332991 combined with vemurafenib that will be associated with a prespecified proportion of patients experiencing a Dose-Limiting Toxicity (DLT), ie, 1/3.

NCT02202200 Melanoma BRAF V600E/K Mutated CDNKN2A Loss Defined
MeSH: Melanoma
HPO: Cutaneous melanoma Melanoma

1 Interventions

Name: PD- 0332991

Description: PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients

Type: Drug

PD-0332991


Primary Outcomes

Description: DLTs, serious adverse events and adverse events leading to treatment discontinuations will be determined as follows: Any grade 3 or more non-haematological toxicity excluding: Grade 3 asymptomatic increase in liver function tests (AST, ALT, ALP) reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement. Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. 5HT3 antagonists and corticosteroids). Grade 3 diarrhoeas if encountered despite adequate and optimal anti diarrhoea therapy. Confirmed grade 3 QTc prolongation (QTc >500 msec) that persists after correction of other possible causes such as electrolyte imbalance Grade 4 hyperlipidemia if it is encountered despite adequate and optimal therapy. Any grade 4 neutropenia of > 5 days duration, or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia > 1 day, or grade 3 with bleeding.

Measure: Occurrence within the first 2 cycles of treatment of a DLT

Time: 42 Days

Secondary Outcomes

Description: Occurrence of clinical benefit (defined as Complete Response (CR), Partial Response (PR) or stable disease (SD)) and progressive disease based on the best overall response which depends on the tumour evaluations assessed using RECIST at the end of each 2 cycles.

Measure: Efficacy

Time: 42 Days

Description: survival

Measure: 1 year survival rate

Time: 1 year

Description: Occurrence of clinically significant changes in a laboratory parameter and/or vital signs judged to be related to the trial medication within the first 6 months.

Measure: Tolerance

Time: 6 months

Other Outcomes

Description: Changes from baseline of ANC and platelet levels Efficiency on the cell-cycle machinery and proliferation (tumor sample) Induction of senescence: will be evaluated using the senescence β-Galactosidase assay (Cell Signaling Technology) Induction of apoptosis: will be performed using TUNEL staining with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore).

Measure: Pharmacodynamic

Time: 42 days

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 V600E

Changes from baseline of ANC and platelet levels Efficiency on the cell-cycle machinery and proliferation (tumor sample) Induction of senescence: will be evaluated using the senescence β-Galactosidase assay (Cell Signaling Technology) Induction of apoptosis: will be performed using TUNEL staining with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore).. Inclusion Criteria: - Age > 18 years - Stage IV or un-resectable stage III melanoma - Presence of BRAF V600E/K mutation and CDNKN2A loss and expression of Rb using immunohistochemistry in a recent metastatic sample (< 6 months) - A previous exposure to BRAF inhibitor or combination of BRAF and MEK inhibitors therapy is allowed unless it has been stopped more than 3 months before study enrolment(This will defined the two strata of the trial) - No previous therapy by MEK inhibitor unless associated with BRAF inhibitors - No previous therapy with the AKT/PI3K pathway inhibitor - Patients should have a tumour available for repeated biopsies for pharmacodynamics evaluation - Life expectancy of > 3 months - ECOG performance status <2 - Signed informed consent - Patient with health insurance coverage - No patient under guardianship or curators Exclusion Criteria: - Inadequate hepatic function defined as serum bilirubin>25 μmol/l, transaminases > 3.0 times the upper limit of normal (ULN) or 5ULN in cases of liver metastases; - Inadequate bone marrow function defined as absolute neutrophil count<1500/mcl, platelets<150000/mcl and haemoglobin<8g/dL - Inadequate renal function with serum creatinine>2.0mg/dl) --- V600E ---

- Chemotherapy, immunotherapy within 4 weeks - Drugs interfering with PD-0332991 and vemurafenib metabolism - Malabsorption syndrome or other condition that would interfere with enteral absorption - Congenital long QT syndrome or screening QTc > 470 msec - Need for chronic corticosteroid therapy of ≥10 mg of prednisone per day Inclusion Criteria: - Age > 18 years - Stage IV or un-resectable stage III melanoma - Presence of BRAF V600E/K mutation and CDNKN2A loss and expression of Rb using immunohistochemistry in a recent metastatic sample (< 6 months) - A previous exposure to BRAF inhibitor or combination of BRAF and MEK inhibitors therapy is allowed unless it has been stopped more than 3 months before study enrolment(This will defined the two strata of the trial) - No previous therapy by MEK inhibitor unless associated with BRAF inhibitors - No previous therapy with the AKT/PI3K pathway inhibitor - Patients should have a tumour available for repeated biopsies for pharmacodynamics evaluation - Life expectancy of > 3 months - ECOG performance status <2 - Signed informed consent - Patient with health insurance coverage - No patient under guardianship or curators Exclusion Criteria: - Inadequate hepatic function defined as serum bilirubin>25 μmol/l, transaminases > 3.0 times the upper limit of normal (ULN) or 5ULN in cases of liver metastases; - Inadequate bone marrow function defined as absolute neutrophil count<1500/mcl, platelets<150000/mcl and haemoglobin<8g/dL - Inadequate renal function with serum creatinine>2.0mg/dl) --- V600E ---

- Chemotherapy, immunotherapy within 4 weeks - Drugs interfering with PD-0332991 and vemurafenib metabolism - Malabsorption syndrome or other condition that would interfere with enteral absorption - Congenital long QT syndrome or screening QTc > 470 msec - Need for chronic corticosteroid therapy of ≥10 mg of prednisone per day Melanoma BRAF V600E/K Mutated CDNKN2A Loss Defined Melanoma null --- V600E ---



HPO Nodes


HPO:
Cutaneous melanoma
Genes 15
HRAS MITF CDKN2A BRAF NRAS NRAS WRN CDKN2A CXCR4 BAP1 POLH CDK4 ERCC3 XPC MC1R
Melanoma
Genes 98
MGMT NRAS POT1 NRAS XPA CTSC BRCA1 SDHC ERCC4 CXCR4 RAD51C CDKN2B ERCC3 XPC PALLD ERCC2 ERCC2 CHEK2 CDKN2A RAD51D GNAQ SDHD KRAS MBTPS2 BAP1 BAP1 CYSLTR2 RNF43 BAP1 CDKN2A PTPN11 CDK4 BRCA2 ERCC3 MITF TERF2IP ERCC4 CHEK2 BRCA1 TRPV3 POT1 OCA2 TERT CDKN2A AKT1 CDKN2A SF3B1 ERCC6 ERCC5 ERCC5 MDM2 BRCA2 BAP1 GNA11 ACD BRIP1 HRAS MRE11 BRAF TYR TP53 KLLN SEC23B PTEN PIK3CA XPA PERP MITF RAF1 BRAF POLH TP53 BARD1 NRAS SMAD4 RAD50 DDB2 ERCC2 NBN TERT MC1R SLC45A2 WRN PALB2 DDB2 PALB2 CDKN2A SDHB MC1R RAD51 TP53 XPC ERCC3 PTEN CDKN2A POLH CDK4 MC1R